243 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education

    • Science
    • 3.7 • 3 Ratings

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

    Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

    Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion of this activity, participants should be better able to: Summarize the genetic etiology, diverse clinical symptomatology, and diagnostic criteria of neurofibromatosis type 1 (NF1), Cite the current evidence from pivotal clinical trials on MEK inhibitors and other targeted therapies for the treatment of NF1-related PNs and other tumors in pediatric populations, Select personalized treatment plans using MEK inhibitors and other targeted therapies in pediatric populations with NF1-related plexiform neurofibromas (PNs) and other tumors based on prognostic information, safety considerations, and the latest evidence and guideline recommendations, Develop a management plan for the unique spectrum of adverse events associated with novel therapeutics including MEK inhibitors in pediatric patients with NF1-associated tumors.

    • 1 hr
    Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

    Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

    Go online to PeerView.com/GWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. Remarkable data have emerged from several immunotherapy trials in perioperative settings and FDA has granted new regulatory approvals for both neoadjuvant and adjuvant immunotherapy regimens, effectively establishing new standards of care in early-stage NSCLC. Still, many questions remain on how to transition these exciting advances to practice and improved patient outcomes in real-world setting. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? These and other essential topics are addressed by two leading experts in thoracic surgery in this PeerView educational activity based on a recent live event. Watch this stimulating discussion of practice-changing data on perioperative immunotherapy, surgical implications and applicability to practice, and how to make the most of ICIs as part of multimodal management of resectable NSCLC. Watch intriguing debates framed by real cases and discussion points selected to highlight the practicalities and challenges of integrating perioperative immunotherapy into practice. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings, Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy, Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions, Integrate best practices for multidisciplinary communication and collaboration to enhance appropriate incorporation of immunotherapies into multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.

    • 48 min
    Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

    Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

    Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. [Activity_Description]The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

    • 1 hr 31 min
    Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

    Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

    Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

    • 1 hr 4 min
    Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma

    Jonathan Corren, MD - Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma

    Go online to PeerView.com/FSQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of airway hyper-responsiveness in severe uncontrolled asthma. Upon completion of this activity, participants should be better able to: Compare the pathophysiology of airway inflammation with airway hyper-responsiveness (AHR) and their clinical manifestations in patients with severe asthma, Apply insights with regard to the role of AHR, as well as recent clinical evidence concerning the efficacy of biologic agents in addressing AHR, to the management of patients with severe asthma.

    • 27 min
    Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

    Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

    Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it’s on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what’s to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

    • 1 hr 26 min

Customer Reviews

3.7 out of 5
3 Ratings

3 Ratings

Top Podcasts In Science

Alie Ward
Hidden Brain
Jordan Harbinger
Vox
Sam Harris
PRX and Greater Good Science Center

More by PeerView Press

PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education
PVI, PeerView Institute for Medical Education